PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Trial Profile

PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Vitespen (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HeatShock
  • Most Recent Events

    • 02 Jun 2015 Results on response to therapy and gene expression presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 01 Jun 2015 Data was presented in 2015 ASCO Annual Meeting, per Agenus media release.
    • 01 Jun 2015 Results published in the Agenus Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top